A5014641457- Chronic Obstructive Pulmonary Disease (COPD) Research
- Asthma and respiratory diseases
- Inhalation and Respiratory Drug Delivery
- Respiratory and Cough-Related Research
- Respiratory Support and Mechanisms
- Chronic Disease Management Strategies
- Acute Myocardial Infarction Research
- Nursing Diagnosis and Documentation
- COVID-19 and healthcare impacts
- Smoking Behavior and Cessation
- Breastfeeding Practices and Influences
- Healthcare Policy and Management
- Delphi Technique in Research
- Health Promotion and Cardiovascular Prevention
- Pulmonary Hypertension Research and Treatments
- Cervical Cancer and HPV Research
- Global Health Care Issues
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Health and Mental Health
- Emergency and Acute Care Studies
- Healthcare cost, quality, practices
- Acute Kidney Injury Research
- Cardiovascular Function and Risk Factors
- Economic and Environmental Valuation
- Health and Wellbeing Research
Chief Scientist Office
2025
Health Economics and Outcomes Research (United Kingdom)
2022-2024
GlaxoSmithKline (United Kingdom)
2020-2024
Middlesex University
2023-2024
Adelphi Group (United Kingdom)
2023
University of Birmingham
2020
Imperial College London
2015-2020
GlaxoSmithKline (India)
2020
Bristol-Myers Squibb (United Kingdom)
2019-2020
Southend University Hospital NHS Foundation Trust
2019
Acute exacerbations of chronic obstructive pulmonary disease (AECOPDs) are important adverse events in the natural history (COPD).To investigate AECOPDs over 10 years follow-up.We identified 99,574 patients with COPD from January 1, 2004, to March 31, 2015, UK Clinical Practice Research Datalink. We defined moderate as those managed outside hospital and severe requiring hospitalization. During baseline period (first year follow-up), were grouped according number severity then followed for a...
Background Acute Exacerbations of COPD (AECOPD) identified from electronic healthcare records (EHR) are important for research, public health and to inform utilisation service provision. However, there is no standardised method identifying AECOPD in UK EHR. We aimed validate the recording Methods randomly selected 1385 patients with Clinical Practice Research Datalink. dates possible based on 15 different algorithms between January 2004 August 2013. Questionnaires were sent GPs asking...
Background Smoking in pregnancy and/or not breastfeeding have considerable negative health outcomes for mother and baby. Aim To understand incentive mechanisms of action smoking cessation breastfeeding, develop a taxonomy identify promising, acceptable feasible interventions to inform trial design. Design Evidence syntheses, primary qualitative survey, discrete choice experiment (DCE) research using multidisciplinary, mixed methods. Two mother-and-baby groups disadvantaged areas collaborated...
Rationale: Previous studies have suggested that acute exacerbations of chronic obstructive pulmonary disease (COPD) may be associated with increased risk myocardial infarction and ischemic stroke.Objectives: We aimed to quantify the risks stroke both moderate severe exacerbation, investigate factors modify these risks.Methods: performed a self-controlled case series rates after exacerbation compared stable time, within individuals. The participants were 5,696 adults COPD first (n = 2,850) or...
Accurate identification of hospitalizations for acute exacerbations chronic obstructive pulmonary disease (AECOPD) within electronic health care records is important research, public health, and to inform utilization service provision. We aimed develop a strategy identify AECOPD in secondary data investigate the validity strategies primary data.We identified patients with (COPD) Clinical Practice Research Datalink (CPRD) linked Hospital Episodes Statistics (HES) data. used discharge...
Patients with chronic obstructive pulmonary disease (COPD) have increased mortality following myocardial infarction (MI) compared patients without COPD. We investigated the extent to which differences in recognition and management after MI could explain difference.300 161 a first between 2003 2013 were identified UK Myocardial Ischaemia National Audit Project database. Logistic regression was used compare hospital at 180 days postdischarge Variables relating inhospital factors (delay...
Triple therapy comprising a long-acting muscarinic antagonist, β2-agonist and inhaled corticosteroid is recommended for patients with chronic obstructive pulmonary disease (COPD) who continue to experience frequent exacerbations or symptoms whilst receiving dual therapy. Adherence persistence multiple-inhaler triple (MITT) known be poor. This study assessed comparative adherence single-inhaler (SITT) versus MITT in real-world setting England.This was retrospective cohort using linked primary...
Background Identifying correlates of cause-specific mortality in patients with chronic obstructive pulmonary disease (COPD) may aid the targeting therapies to reduce mortality. We determined factors associated causes death a primary care COPD population. Methods Clinical Practice Research Datalink Aurum was linked Hospital Episode Statistics and certificate data. People alive between 1 January 2010 2020 were included. Patient characteristics defined before start follow-up: (a) frequency...
Background: The diagnosis of COPD is dependent upon clinical judgment and confirmation the presence airflow obstruction using spirometry. Spirometry now routinely available; however, spirometry incorrectly performed or interpreted can lead to misdiagnosis. We aimed determine whether undertaken in primary care for patients suspected have was sufficient quality their correctly interpreted. Methods: Two chest physicians re-read all spirometric readings both procedure interpretation, received as...
There is limited information regarding multidimensional relationships between asthma control and health-related quality of life (HRQoL), work productivity, symptom burden in Japan. Furthermore, systematic qualitative investigations about have not been performed. This cross-sectional, mixed-methods study included Japanese patients (≥ 20 years) with adherent to inhaled corticosteroids/long-acting β2-agonists (ICS/LABA). The primary endpoint was impact on HRQoL, measured using the Asthma Health...
Abstract Background There is a need for real-world data describing the frequency and impact of moderate asthma exacerbations in patients receiving inhaled corticosteroids/long-acting β 2 -agonists (ICS/LABA). The Salford Lung Study (SLS) associated extension study (Ext-SLS) evaluated ICS/LABA versus existing maintenance therapy adults with asthma. This analysis assessed from Ext-SLS. Methods retrospective cohort analysed linked primary secondary care patient questionnaire enrolled Ext-SLS...
Abstract Background Triple therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) who remain symptomatic despite dual therapy. The optimal timing of triple following an exacerbation COPD unknown. outcomes prompt (≤ 30 days) vs. delayed (31–180 initiation single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) were examined. Methods This was a retrospective cohort study linked English primary (Clinical Practice Research Datalink) secondary...
Abstract Inhaled corticosteroids (ICS) plus long-acting β 2 -agonists (LABA) are recommended for maintenance-only or maintenance and reliever therapy (MART) in patients with asthma. However, real-world data on ICS/LABA as MART limited. This study characterized clinical, economic, humanistic burdens of asthma Canada, China, Europe, Japan, the US, using collected from physicians via a cross-sectional survey (Asthma Disease Specific Programme). Patients were ≥18 years age physician-confirmed...
Cardiovascular disease is a common cause of death in patients with chronic obstructive pulmonary (COPD) and key target for improving outcomes. However, there are concerns that COPD may not have enjoyed the same mortality reductions from acute myocardial infarction (AMI) recent decades as general population. This has raised questions about differences presentation, management outcomes compared to non-COPD patients. The evidence points an increased risk after AMI COPD, but it unclear what...
Purpose: Clinical guidelines for COPD management suggest pharmacologic treatment algorithms based on symptoms and exacerbation history. As previous research has suggested that prescribing patterns are not always aligned with these recommendations, this study investigated the burden of disease in patients receiving, persisting on, new inhaled maintenance therapy. Patients Methods: This was a retrospective observational using two linked electronic databases containing health records England....
Background Compared with multiple-inhaler triple therapy (MITT), single-inhaler (SITT) fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) demonstrated improved lung function and meaningful improvements in chronic obstructive pulmonary disease (COPD) Assessment Test score. This real-world study compared the effectiveness of switching patients COPD England from MITT to once-daily SITT FF/UMEC/VI by evaluating rates exacerbation, healthcare resource use (HCRU) associated direct medical...
Real-world data assessing characteristics of patients with asthma initiating inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β